Altre lingue Halozyme Therapeutics, Inc.

Azioni

HALO

US40637H1095

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
38,57 ^USD	+0,29%		-0,18%	+4,36%

25/04	Halozyme Therapeutics, Inc. annuncia l'elezione di Mahesh Krishnan, M.D., nel suo Consiglio di Amministrazione	CI
18/04	L'insider di Halozyme Therapeutics ha venduto azioni per un valore di 768.390 dollari, secondo un recente deposito SEC	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Mahesh Krishnan Elected to Halozyme's Board of Directors	25/04
Halozyme Therapeutics, Inc. Announces the Election of Mahesh Krishnan, M.D. to its Board of Directors	25/04
Halozyme to Report First Quarter 2024 Financial and Operating Results	23/04
Halozyme Therapeutics Insider Sold Shares Worth $768,390, According to a Recent SEC Filing	18/04
Halozyme Therapeutics Insider Sold Shares Worth $839,100, According to a Recent SEC Filing	13/03
Halozyme to Participate in Upcoming Investor Conferences	27/02
Halozyme Therapeutics Q4 Adjusted Earnings, Revenue Rise; Reiterates 2024 Guidance	21/02
Halozyme Therapeutics: Q4 Earnings Snapshot	20/02
Tranche Update on Halozyme Therapeutics, Inc.'s Equity Buyback Plan announced on December 9, 2021.	20/02
Earnings Flash (HALO) HALOZYME THERAPEUTICS Reports Q4 EPS $0.82, vs. Street Est of $0.83	20/02
(HALO) HALOZYME THERAPEUTICS Forecasts Fiscal Year 2024 Revenue Range $915M - $985M	20/02
Earnings Flash (HALO) HALOZYME THERAPEUTICS Reports Q4 Revenue $230M, vs. Street Est of $231.1M	20/02
Halozyme Therapeutics Guides For 2024 EPS of $3.55-$3.90, vs CIQ Analyst Consensus of $3.64/Share	20/02
Halozyme Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	20/02
Halozyme Therapeutics, Inc. announces an Equity Buyback for $750 million worth of its shares.	20/02
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS	20/02
Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	20/02
Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results	08/02
Halozyme Therapeutics, Inc. authorizes a Buyback Plan.	01/02
Halozyme Announces Takeda Received European Commission Approval for HYQVIA Co-formulated with ENHANZE as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy	30/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Halozyme Therapeutics, Inc.

Azioni

HALO

US40637H1095

Altre lingue

Filtri